Navigation Links
Taxane in Medical News

Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer

...nt demographics and key ovarian cancer disease characteristics, including age, ECOG Performance Status, presence of bulky disease and history of prior taxane therapy. A greater number of patients (13, 20%) had platinum refractory disease on the TELCYTA plus PLD arm compared to (8, 13%) with the PLD arm. ...

Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009

...tients with advanced or metastatic breast cancer whose tumors overexpress HER2/ErbB2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab. On June 10, 2008, the European Commission granted a conditional marketing authorization for lapatinib in all 27 European Union (E.U.)...

Drug May Help Against Inflammatory Breast Cancer

...kin of more than two-thirds of the breast, tenderness, hardening and warming of the breast. For patients resistant to conventional anthracycline or taxane and trastuzumab, treatment options are limited. Lapatinib inhibits HER2, a protein that's expressed much more in inflammatory breast cancer than in ot...

Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer

...greed to by FDA, will assess the capacity of farletuzumab to extend progression free survival and overall survival in combination with carboplatin and taxane at two different dose levels of farletuzumab. The study will be conducted as a randomized, double-blind, placebo-controlled trial. Morphotek expects ...

Non-Hormonal Therapies Aid Breast Cancer Patients

...n overall death, compared with older single-agent chemotherapy. Single drug taxane treatment led to a relative risk reduction of 33 percent, while a combination of a taxane with capecitabine or gemcitabine led to a 51 percent relative risk reductio...

Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium

...ong North Carolina metastatic breast cancer patients treated with Xeloda or taxane monotherapy. -- Dec. 14, 7:00 to 9:00 a.m., [Poster No. 6107], Cape...urvival outcome is similar for first-line chemotherapy with capecitabine or taxane for metastatic breast cancer (Lead Author: Gretchen Kimmick) The ma...

FDA Accepts Genta's NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Also in the May 27 JNCI

...acted follow-up, the authors write. A retrospective analysis of the data failed to detect a subgroup of patients who were more likely to respond to taxane therapy on the basis of their tumors expression of the estrogen receptor and HER2. In an accompanying editorial, Clifford Hudis, M.D., and Chau Dan...

Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel

..." About Tesetaxel Tesetaxel is a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. However, bo...ule, tesetaxel was developed to maintain the high antitumor activity of the taxane drug class while eliminating infusion reactions, reducing neuropathy, and i...

New study of targeted therapies for breast cancer -- model for global clinical trials

...he treatment of advanced or metastatic HER2-positive breast cancer in patients who had received prior therapy with three agents -- an anthracycline, a taxane and Herceptin. GlaxoSmithKline is providing the study drug, as well as additional financial support for the ALTTO trial. All drugs carry potential sid...
Taxane in Medical Technology

FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane

Clinical Studies Expected to Restart in Second Half 2008 BERKELEY HEIGHTS, N.J., June 23 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced that the Company has received notification from the U.S. Food and Drug Administration (FDA) that Genta may resume c...

ADVENTRX Announces Results From ANX-514 Bioequivalence Study

...mary endpoint of the study, was not demonstrated based on benchmark regulatory standards. "Following discussions with clinicians and experts in taxane pharmacokinetics, we believe that the increased blood-levels of docetaxel, which we observed solely during the first hour of a 168-hour observation pe...

BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial

...the U.S. Tavocept Trial involved cisplatin and the taxane drug docetaxel while the Japan Tavocept Trial involved cisplatin and the taxane drug paclitaxel, BioNumerik has also now observed ...reatment regimens utilizing two different types of taxane chemotherapy drugs. "It is also important to con...

Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting

...10620/ENMDLOGO ) For this Phase 2 single agent, open label study, a total of 65 patients who had previously received at least one anthracycline and taxane therapy were enrolled. 55 patients were evaluable for tumor response. Of the evaluable patients, the antitumor activity observed with MKC-1 included 3...

ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)

...ts who are Herceptin receptor (Her2/neu) negative and who have failed prior taxane and anthracycline therapies. Data available from 31 patients indicated a 23...n in patients with advanced breast cancer who have failed anthracycline and taxane chemotherapies with clearly defined criteria. The primary endpoint for the ...

Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies

...ongly predicted benefit from treatment with docetaxel (Taxotere), a type of taxane commonly used for breast cancer therapy. A genomic classifier predicting di... biology of breast cancer and now, possibly, treatment benefit for a common taxane regimen with our ongoing study of the utility of Oncotype DX and additional...

Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...
Taxane in Biological News

Common chemotherapy drug triggers fatal allergic reactions

...rse Event Report System between 1997 and 2007 with 109 (38 percent) deaths in patients who received Cremophor-based paclitaxel, a solvent-administered taxane chemotherapy. Adverse event reports generally only represent from 1 to 10 percent of actual incidence, so the number of hypersensitivity reactions...

Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer

...edian of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine. About Study 211 Study 211 is a Phase II, open-label, s...y advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last ch...

Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer

... Berlin, Germany: Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centr...

Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors

...searchers now plan to investigate the effects of adjuvant and neo-adjuvant treatments in women with BRCA1/2-associated breast cancers, and to evaluate taxane and platinum therapies further. ...
Taxane in Biological Technology

Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane

Company Also Completes FDA Submission for Removal of Clinical Hold BERKELEY HEIGHTS, N.J., June 10 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced that the Company has received notice of allowances for two major patents from the European Patent Office for i...

First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer

...gle arm studies encompassing two treatment regimens (every 14 days or every 21 days). Patients include those with metastatic breast cancer with prior taxane treatment, those with metastatic, platinum-resistant ovarian cancer and those with metastatic cervical cancer. The trials are designed to evaluate th...

Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer

...he potential for additional uses of picoplatin as a combination therapy in the treatment of non-small cell lung and ovarian cancers where platinum and taxane combinations are currently used." About Picoplatin Picoplatin has an improved safety profile relative to existing platinum-based cancer therapies ...

Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the Uni...

Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008

...udy, performed in Serbia and Poland, MVA-BN(R)-HER2 is being evaluated following first or second-line chemotherapy or in combination with single-agent taxane chemotherapy. Both studies evaluate treatment of metastatic breast cancer patients, whose tumors overexpress HER2. Patients are vaccinated 3 times, at...

Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights

...w us to resume clinical trials with a leading oral taxane that addresses a large, well-characterized market....e proposed indication. Tesetaxel: A Leading Oral taxane with Anticancer Activity In other regulatory act...esetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and d...

Genta Announces Second Quarter 2008 Financial Results and Conference Call

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the Uni...

Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia

...tial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi- synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights

...strategy -- Tesetaxel in-licensed -- leading oral taxane and new clinical-stage product -- FDA provide...s to tesetaxel has provided us with a leading oral taxane that addresses a very large and well-characterized...e efficacy and safety. Tesetaxel: A Leading Oral taxane with Anticancer Activity Tesetaxel is the latest...
Other Tags
(Date:8/1/2015)... , ... August 01, 2015 , ... Lume Wellness creators ... is free to download on the Apple AppStore. , The app is designed ... mood, thus acting as a tool to view personal health and use this information ...
(Date:7/31/2015)... ... 31, 2015 , ... That’s right, the STASH awards have ... The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured in High ... that have stood the test of time. These include lighting products, organic and ...
(Date:7/31/2015)... ... ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA on Sunday, ... Bowl. In the two weeks that separate the conference championships and the Super Bowl, there ... game will mark the 50th time it has been held and the festivities will take ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... its new store run by GoodThreads. The store can be accessed by visiting ... designs, many of which are customizable. The best part: whenever a product is ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... workshop at its new True North Conference Center. The medical community, social workers, ... Jacksonville community may be more aligned in the effort to better understand and ...
Breaking Medicine News(10 mins):Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a ... a revised version of one of its first 30 second commercials ... in New York , Chicago ... Francisco metro areas.    , , , ... all the cards in your wallet and keep your identity secure. ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
Other Contents